- Home
- HGTY vs PCRX Comparison
HGTY vs PCRX Comparison
Compare HGTY & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HGTY | PCRX |
|---|---|---|
| Founded | 1984 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | HGTY | PCRX |
|---|---|---|
| Price | $12.65 | $19.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $14.00 | ★ $35.33 |
| AVG Volume (30 Days) | 107.8K | ★ 1.0M |
| Earning Date | 03-03-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 241.11 | N/A |
| EPS | 0.36 | ★ 0.47 |
| Revenue | ★ $1,360,017,000.00 | $716,791,000.00 |
| Revenue This Year | $18.41 | $6.21 |
| Revenue Next Year | N/A | $8.26 |
| P/E Ratio | ★ $35.18 | $40.65 |
| Revenue Growth | ★ 17.92 | 3.14 |
| 52 Week Low | $8.03 | $18.92 |
| 52 Week High | $14.00 | $27.64 |
Technical Indicators
Market Signals| Indicator | HGTY | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.12 | 25.61 |
| Support Level | $12.50 | $22.52 |
| Resistance Level | $12.93 | $22.56 |
| Average True Range (ATR) | 0.40 | 1.30 |
| MACD | -0.09 | -0.73 |
| Stochastic Oscillator | 8.00 | 2.92 |
Price Performance
Historical ComparisonAbout HGTY Hagerty Inc.
Hagerty Inc is a provider of specialty automotive insurance. The company underwrites, sells, and services classic car and enthusiast vehicle insurance policies. Substantial revenue is derived from Commission and fees. Geographically it serves Europe, Canada, and the United States.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.